Skip to contentL
Ligand Pharmaceuticals Inc
L
LGNDLigand Pharmaceuticals Inc Q2 2017 · 10-Q
Revenue$90.04M$90.04M+361.3% vs Q2 2016 Net Income$73.16M$73.16MN/M vs Q2 2016 EPS Diluted$2.99$2.99N/M vs Q2 2016 Operating Income$13,015,000+227.9% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ligand Pharmaceuticals Inc · CIK 886163 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$10,274,000+7.2% Margins · derivedOperating margin14.5%−5.9 pt vs Q2 2016
Net margin81.3%+112.9 pt vs Q2 2016
ended Jun 30, 2017 · filed Aug 9, 2017 · 40 d after period end